281 related articles for article (PubMed ID: 25245375)
1. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
3. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
Cheng W; Zhou J; Tian X; Zhang X
Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
[TBL] [Abstract][Full Text] [Related]
4. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
6. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
Cheng W; Wang M; Tian X; Zhang X
Eur J Med Chem; 2017 Jan; 126():476-490. PubMed ID: 27914362
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
8. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EGF/HER Ligand-Receptor System in Cancer.
Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor as a target for anti-cancer agent design.
Cao J; Fang H; Wang B; Ma C; Xu W
Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress.
Sharma B; Singh VJ; Chawla PA
Bioorg Chem; 2021 Nov; 116():105393. PubMed ID: 34628226
[TBL] [Abstract][Full Text] [Related]
12. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
13. Virtual high throughput screening of natural peptides against ErbB1 and ErbB2 to identify potential inhibitors for cancer chemotherapy.
Patnaik SK; Ayyamperumal S; Jade D; Palathoti N; Akey KS; Jupudi S; Harrison MA; Ponnambalam S; Mj N; Mjn C
J Biomol Struct Dyn; 2024 Jul; 42(11):5551-5574. PubMed ID: 37387589
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
[TBL] [Abstract][Full Text] [Related]
15. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.
Abourehab MAS; Alqahtani AM; Youssif BGM; Gouda AM
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771085
[TBL] [Abstract][Full Text] [Related]
16. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of action and preclinical development of afatinib].
Diz Taín P; González AL; García-Palomo A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
[TBL] [Abstract][Full Text] [Related]
18. Review on EGFR Inhibitors: Critical Updates.
Singh D; Attri BK; Gill RK; Bariwal J
Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
[TBL] [Abstract][Full Text] [Related]
19. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds.
Yu-Jing YJ; Zhang CM; Liu ZP
Anticancer Agents Med Chem; 2012 May; 12(4):391-406. PubMed ID: 22043991
[TBL] [Abstract][Full Text] [Related]
20. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
